Sanofi and GSK delay vaccine launch to late 2021
The companies said the vaccine, which is a different type to the Pfizer-BioNTech one, showed an insufficient immune response in older people
11 December 2020 - 12:24
Paris — Sanofi and GlaxoSmithKline (GSK) have said clinical trials of their Covid-19 vaccine showed an insufficient immune response in older people, delaying its launch to late in 2021 and marking a setback in the global fight against the pandemic.
The announcement on Friday, which highlighted the challenges of developing shots at record speed, hinders efforts to develop the multiple options that experts say the world needs to counter a disease that has killed more than 1.5-million people...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.